Skip to main content
Premium Trial:

Request an Annual Quote

KWS SAAT Licenses Genome Engineering Technology from Two Blades

NEW YORK (GenomeWeb News) – The Two Blades Foundation today said it has completed a non-exclusive licensing agreement with KWS SAAT covering Two Blades' Transcription Activator Like effector code technology for genome engineering in certain crops.

The technology is for making specific changes in genomes based on novel sequence-specific DNA-binding proteins. TAL effector proteins can be designed to recognize almost any DNA sequence of interest and specific locations in the genome can be targeted for gene replacement and gene function modulation.

Two Blades holds exclusive rights to the technology in plants. The TAL Code technology was discovered by researchers at Martin-Luther University in Halle, Germany.

Financial and other terms of the deal were not disclosed.

Two Blades reached similar deals earlier this year for the TAL Code technology with Bayer CropScience, Monsanto, and Syngenta. The not-for-profit corporation, based in Evanston, Ill., develops durable disease resistance in agricultural crops.

KWS SAAT is a plant breeding firm based in Einbeck, Germany.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.